Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04964505 · ClinicalTrials.gov registry record · Phase 1
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
A Phase 1 study, sponsored by Brian Jonas.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04964505 is a Phase 1 study that was terminated before completion, run by Brian Jonas. The registered enrollment target is 16 participants.
The verdict
NCT04964505, a Phase 1 study, was terminated before completion, sponsored by Brian Jonas.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase I trial evaluates the side effects of uproleselan, azacitidine, and venetoclax in treating older or unfit patients with treatment naive acute myeloid leukemia. Uproleselan may help block the formation of growths that may become cancer. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving uproleselan with azacitidine and venetoclax may help kill more cancer cells.
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Uproleselan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-07-02 |
| Est. Completion | 2025-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04964505
The ClinicalTrials.gov registry entry for NCT04964505 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brian Jonas, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT04964505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04964505 about?
NCT04964505 is a clinical study titled "Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia". This phase I trial evaluates the side effects of uproleselan, azacitidine, and venetoclax in treating older or unfit patients with treatment naive acute myeloid leukemia. Uproleselan may help block the formation of growths that may become cancer. Chemotherapy drugs, such as azacitidine, work in diff...
What is the current status of trial NCT04964505?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-07-02. Estimated completion is 2025-10-07.
What interventions are being tested in trial NCT04964505?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Uproleselan (DRUG).
Who is sponsoring clinical trial NCT04964505?
This trial is sponsored by Brian Jonas, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.